What does CORBIOPHARM do?

CORBIOPHARM is a logistics company in Bouillon. Public Limited, started on 23 January 1984, 1 establishment.

What is the address of CORBIOPHARM?

The registered office of CORBIOPHARM is located at Chemin du Stayi,Corbion 3, 6838 Bouillon.

Is CORBIOPHARM still active?

Yes. According to the CBE (30 October 2026) CORBIOPHARM is active, legal situation “Normale toestand”, started on 23 January 1984.

Is CORBIOPHARM registered on Peppol?

Yes, CORBIOPHARM is registered on the Peppol network with ID 0208:0425205834.

What is the enterprise number of CORBIOPHARM?

The enterprise number of CORBIOPHARM is BE0425205834.

When was CORBIOPHARM founded?

CORBIOPHARM was founded on 23 January 1984.

Who are the directors of CORBIOPHARM?

According to the 2025 annual accounts, the directors of CORBIOPHARM are: MOMA INVEST, Philippe MONHONVAL.

Is CORBIOPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 January 1984; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CORBIOPHARM make in 2025?

CORBIOPHARM posted a profit after taxes of € 26,810 in financial year 2025.

What is the revenue of CORBIOPHARM?

As a small company, CORBIOPHARM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 103,299.

How much does an employee at CORBIOPHARM earn?

The average wage cost per full-time employee at CORBIOPHARM was € 40,900 in 2024: staff costs of € 81,709 for 2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

CORBIOPHARM (Public Limited) - Bouillon - BE0425205834

Dossier CORBIOPHARM, printed on 30 October 2026 from databakkes.be/en/0425205834/corbiopharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CORBIOPHARM from Bouillon, company number BE0425205834, closed financial year 2025 with a result of € 26,810 after tax. For that financial year CORBIOPHARM recorded a gross margin of € 103,299 and equity of € 106,782. Compared with financial year 2024, the result moved from € -13,909 to € 26,810. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What it is worth Growing

€ 106,782

▲ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 26,810

▲ still € 13,909 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 139,701

▲ 61% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 12,500 paid out

47 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Wage cost

€ 57,464

▼ 30% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 13,566

▼ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 140,027

▲ 35% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 12,515

▲ 9% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 80,236 Gross margin 2022: € 80,236 First fiscal year in the series	€ 165,679 Gross margin 2023: € 165,679 ▲ 106% vs 2022 (€ 80,236) Favourable step	€ 84,982 Gross margin 2024: € 84,982 ▼ 49% vs 2023 (€ 165,679) Unfavourable step	€ 103,299 Gross margin 2025: € 103,299 ▲ 22% vs 2024 (€ 84,982) Favourable step	▲ 22%
Profit after taxes	€ -8,567 Profit after taxes 2022: € -8,567 First fiscal year in the series	€ 57,790 Profit after taxes 2023: € 57,790 ▲ € 66,357 vs 2022 (€ -8,567) Favourable step	€ -13,909 Profit after taxes 2024: € -13,909 ▼ € 71,699 vs 2023 (€ 57,790) Unfavourable step	€ 26,810 Profit after taxes 2025: € 26,810 ▲ € 40,719 vs 2024 (€ -13,909) Favourable step	▲ € 40,719
Equity	€ 96,591 Equity 2022: € 96,591 First fiscal year in the series	€ 106,381 Equity 2023: € 106,381 ▲ 10% vs 2022 (€ 96,591) Favourable step	€ 92,472 Equity 2024: € 92,472 ▼ 13% vs 2023 (€ 106,381) Unfavourable step	€ 106,782 Equity 2025: € 106,782 ▲ 15% vs 2024 (€ 92,472) Favourable step	▲ 15%
Total debts	€ 247,948 Total debts 2022: € 247,948 First fiscal year in the series	€ 274,250 Total debts 2023: € 274,250 ▲ 11% vs 2022 (€ 247,948) Unfavourable step	€ 169,010 Total debts 2024: € 169,010 ▼ 38% vs 2023 (€ 274,250) Favourable step	€ 215,319 Total debts 2025: € 215,319 ▲ 27% vs 2024 (€ 169,010) Unfavourable step	▲ 27%
Cash	-	-	€ 86,638 Cash 2024: € 86,638 First fiscal year in the series	€ 139,701 Cash 2025: € 139,701 ▲ 61% vs 2024 (€ 86,638) Favourable step	▲ 61%
Land & buildings	€ 10,064 Land & buildings 2022: € 10,064 First fiscal year in the series	€ 6,853 Land & buildings 2023: € 6,853 ▼ 32% vs 2022 (€ 10,064) Unchanged	€ 3,642 Land & buildings 2024: € 3,642 ▼ 47% vs 2023 (€ 6,853) Unchanged	€ 430 Land & buildings 2025: € 430 ▼ 88% vs 2024 (€ 3,642) Unchanged	▼ 88%
Retained profit	€ 34,591 Retained profit 2022: € 34,591 First fiscal year in the series	€ 44,381 Retained profit 2023: € 44,381 ▲ 28% vs 2022 (€ 34,591) Favourable step	€ 30,472 Retained profit 2024: € 30,472 ▼ 31% vs 2023 (€ 44,381) Unfavourable step	€ 44,782 Retained profit 2025: € 44,782 ▲ 47% vs 2024 (€ 30,472) Favourable step	▲ 47%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 48,000 Dividend 2023: € 48,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 48,000) Unchanged	€ 12,500 Dividend 2025: € 12,500 Unchanged (€ 0) Unchanged
Bank debt	€ 41,074 Bank debt 2022: € 41,074 First fiscal year in the series	€ 15,504 Bank debt 2023: € 15,504 ▼ 62% vs 2022 (€ 41,074) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 15,504) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 344,539 Balance sheet total 2022: € 344,539 First fiscal year in the series	€ 380,631 Balance sheet total 2023: € 380,631 ▲ 10% vs 2022 (€ 344,539) Unchanged	€ 261,482 Balance sheet total 2024: € 261,482 ▼ 31% vs 2023 (€ 380,631) Unchanged	€ 322,101 Balance sheet total 2025: € 322,101 ▲ 23% vs 2024 (€ 261,482) Unchanged	▲ 23%
Employees (FTE)	2.3 Employees (FTE) 2022: 2.3 First fiscal year in the series	2.2 Employees (FTE) 2023: 2.2 ▼ 0.1 vs 2022 (2.3) Unchanged	2 Employees (FTE) 2024: 2 ▼ 0.2 vs 2023 (2.2) Unchanged	-

Key figures of CORBIOPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CORBIOPHARM?

What happened at CORBIOPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 28, 2026 New annual accounts for financial year 2025: profit of € 26,810. Source: NBB ↗
2024 MOMA INVEST stepped down as director. NBB
2024 Philippe MONHONVAL stepped down as director. NBB
2018 MOMA INVEST became a director. NBB
2018 Philippe MONHONVAL became a director. NBB
Jan 23, 1984 Start of the company according to the CBE. KBO
Jan 1, 1984 New establishment in Bouillon. KBO

In short

From € 8,567 loss in 2022 to € 26,810 profit in 2025.

Paid € 5,124 in corporate taxes since 2022.

Best year ever: 2023, with € 57,790 profit.

On average € 42,500 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

MOMA INVEST

The stake of MOMA INVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CORBIOPHARM

The shares are held by MOMA INVEST.

Directors

According to the 2025 annual accounts

MOMA INVEST

Managing director

since 2018 · until 2024

Philippe MONHONVAL

Director

Also active at: MOMA INVEST

since 2018 · until 2024

Shareholders

MOMA INVEST

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Chemin du Stayi,Corbion 3

6838 Bouillon

2.023.908.958

Rue du Tambour,Corbion 46

6838 Bouillon

Active since 1 January 1984

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0425.205.834

VAT number

BE 0425.205.834

Registered office

Chemin du Stayi,Corbion 3, 6838 Bouillon

Names & denominations

CORBIOPHARM

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

23 January 1984

Peppol

Active · Active since 3 Dec 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

Activiteiten op het gebied van voeding

Overige activiteiten i.v.m. gezondheidszorg, n.e.g.

Overige menselijke gezondheidszorg, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

CORBIOPHARM

Financials

What happened to CORBIOPHARM?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions